Uncategorized

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that all participating study sites in the Phase IIb study of pirepemat are activated and recruiting patients.

Yuhan Corporation announced on the 30th of May that it has signed an in-license agreement with J INTS BIO for a Tyrosine Kinase Inhibitor targeting HER2, ‘JIN-A04’.

Hinge Bio, Inc., a privately-held biotechnology company, announced that Juha Punnonen, M.D., Ph.D. has joined the company as Chief Development Officer.

ValnevaSE, a specialty vaccine company, announced that its senior management will attend the Jefferies Healthcare Conference, Goldman Sachs Annual Global Healthcare Conference and the Stifel European Healthcare Conference.

Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, published the Annual Report with full year audited consolidated financial results for the year ended 31 December 2022.

Ascentage Pharma announced that the Center for Drug Evaluation of China National Medical Products Administration has recommended olverembatinib, Ascentage Pharma’s lead novel drug candidate, for a Breakthrough Therapy Designation for the treatment of patients with succinate dehydrogenase -deficient gastrointestinal stromal tumor who had received first-line treatment.

Akebia announced it will submit a new NDA targeting CKD patients on dialysis, which will not involve additional trials. 

An improvement in volumes for the health system, especially outpatient surgeries and emergency room visits, didn’t outpace growing expenses, which increased by $804 million year over year in the nine month period.

Check out these hot Boston-based biotech companies hiring now.

Known as Relyvrio in the U.S., Amylyx’s AMX0035 may face a longer road to approval in Europe as the company reported that CHMP could reject its marketing authorization application.